• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA• Launch preparations are underway to bring the second approved golimumab biosimilar to patients acro...
View DetailsGUANGZHOU, China--(BUSINESS WIRE "BAT1706 is the company's second application for marketing approval of a Biosimilar in China, following the approval of Qletli® (adalimumab injection)," said Dr. Li Shengfeng, founder and CEO of Bio-TheraSolutions. "L...
GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company, today announced that the Phase III clinical trial comparing the safety and efficacy of BAT1706 versus Avastin®1 (bevacizumab) met its primary endpoi...
GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd., a fully-integrated pharmaceutical company, today announced that QLETLI® (格乐立®), a biosimilar to Humira® (adalimumab), is now available in China. QLETLI® (格乐立®), the first adalimumab biosim...
